Pallas Capital Advisors LLC Purchases 693 Shares of United Therapeutics Corporation $UTHR

Key Points

• Pallas Capital Advisors LLC increased its stake in United Therapeutics Corporation by 60.8%, holding shares worth approximately $527,000 as of the most recent reporting period.
• Insider sales include COO Michael Benkowitz selling 22,500 shares for about $9.4 million, and EVP Paul A. Mahon selling 11,000 shares, signaling notable insider activity.
• Analysts have raised their price targets for United Therapeutics, with estimates ranging from $463 to $575, indicating strong market expectations for the company's stock.

Pallas Capital Advisors LLC grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 60.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,833 shares of the biotechnology company's stock after acquiring an additional 693 shares during the period. Pallas Capital Advisors LLC's holdings in United Therapeutics were worth $527,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock valued at $1,374,001,000 after acquiring an additional 15,312 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in United Therapeutics by 0.7% during the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company's stock worth $192,571,000 after buying an additional 4,145 shares during the last quarter. Assetmark Inc. increased its stake in United Therapeutics by 20.8% in the first quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock valued at $159,823,000 after purchasing an additional 89,290 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec increased its stake in United Therapeutics by 22.5% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company's stock valued at $147,278,000 after purchasing an additional 87,664 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of United Therapeutics by 46.1% during the first quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company's stock valued at $143,381,000 after buying an additional 146,664 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

UTHR stock traded up $15.33 during midday trading on Tuesday, reaching $430.06. The company had a trading volume of 542,089 shares, compared to its average volume of 576,189. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The company has a market capitalization of $19.40 billion, a P/E ratio of 16.74, a P/E/G ratio of 6.37 and a beta of 0.62. The firm has a 50-day moving average price of $331.90 and a 200-day moving average price of $311.38.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same period last year, the company posted $5.85 EPS. United Therapeutics's revenue for the quarter was up 11.7% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research report on Thursday, September 4th. Finally, Morgan Stanley lowered their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $438.85.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 4,000 shares of the company's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $417.30, for a total value of $1,669,200.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company's stock, valued at approximately $54,249. This represents a 96.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $406.17, for a total transaction of $4,467,870.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $14,939,338.77. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 176,435 shares of company stock worth $65,503,807 in the last ninety days. 10.30% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.